These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32976493)

  • 21. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
    Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ
    AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desimplification of Single Tablet Antiretroviral (ART) Regimens-A Practical Cost-Savings Strategy?
    Krentz H; Campbell S; Gill J
    J Int Assoc Provid AIDS Care; 2019; 18():2325958218822304. PubMed ID: 30672364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons.
    Diaco ND; Strickler C; Giezendanner S; Wirz SA; Tarr PE
    EClinicalMedicine; 2018 Dec; 6():21-25. PubMed ID: 31193647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brief Report: Patients' Experiences and Opinions After Desimplification of Their Single-Tablet Regimens for the Treatment of HIV Infection: A Survey in a Multicentre Cohort.
    Suárez-García I; Ruiz-Algueró M; Alejos B; García-Yubero C; Belza MJ; Espacio R; Hernández J; Muñoz Sánchez J; Garaialde A; Alonso Socas MDM; Alcaraz A; Pierola Ruiz de Galarreta B; Martínez Madrid OJ; Gutiérrez Cuéllar I; Gómez-Ayerbe C; Olalla J; Jarrín I;
    J Acquir Immune Defic Syndr; 2022 May; 90(1):62-68. PubMed ID: 35090156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De-simplifying antiretroviral therapy from a single-tablet to a two-tablet regimen: Acceptance, patient-reported outcomes, and cost savings in a multicentre study.
    Oosterhof P; de Zoete BGJA; Vanhommerig JW; Langebeek N; Gisolf EH; van Hulzen AGW; Lammers AJJ; Weijsenfeld AM; van der Valk M; Grintjes K; van Crevel R; van Luin M; Brinkman K; Burger DM
    HIV Med; 2024 May; ():. PubMed ID: 38712697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative impact of a health insurer-mandated de-simplification from a single-tablet regimen to a two-tablet regimen.
    Oosterhof P; Van Luin M; Brinkman K; Burger DM
    AIDS; 2024 Jul; 38(8):1257-1262. PubMed ID: 38597511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
    Ribera E
    AIDS Rev; 2018; 20(4):179-186. PubMed ID: 30548024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
    Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
    Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
    Winston A; Post FA; DeJesus E; Podzamczer D; Di Perri G; Estrada V; Raffi F; Ruane P; Peyrani P; Crofoot G; Mallon PWG; Castelli F; Yan M; Cox S; Das M; Cheng A; Rhee MS
    Lancet HIV; 2018 Apr; 5(4):e162-e171. PubMed ID: 29475804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost-savings analysis of a candidate universal antiretroviral regimen.
    Ripin D; Prabhu VR
    Curr Opin HIV AIDS; 2017 Jul; 12(4):403-407. PubMed ID: 28383299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment.
    Llibre JM; Clotet B
    AIDS Rev; 2012; 14(3):168-78. PubMed ID: 22833060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
    Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
    Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
    Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
    McComsey GA; Lupo S; Parks D; Poggio MC; De Wet J; Kahl LP; Angelis K; Wynne B; Vandermeulen K; Gartland M; Cupo M; Aboud M;
    AIDS; 2018 Feb; 32(4):477-485. PubMed ID: 29239893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.
    Collins SE; Grant PM; Uwinkindi F; Talbot A; Seruyange E; Slamowitz D; Mugeni A; Remera E; Niyonsenga SP; Nyirimigabo J; Uwizihiwe JP; Dongier P; Muhayimpundu R; Mazarati JB; Zolopa A; Nsanzimana S
    Open Forum Infect Dis; 2016 Sep; 3(3):ofw141. PubMed ID: 27704000
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.